Thus, the results of our study are consistent with the observed effects of conformation-specific EGFR ligands in cancer cell lines and further supported by simulations focused on inhibitor complexes with the active conformation of ΔELREA EGFR, where the restricted αC helix movement resulted in a more compact binding site impacting the interactions and affinity for inhibitors [61]. The gene discussed is EGFR; the disease is cancer.